Clinical Trial Search

Primary: Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) — 7; 25 Participants

Primary: Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population — 83.8; 85.2 Percentage of participants

Primary: Change in Total Median Total Colony Forming Units (CFU) of C. Difficile Identified in the Hospital Room Environment for Each Antibiotic Treatment Group. — 56; 33; 149; 7…

Primary: Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population — 81; 85.7 Percentage of participants

Primary: The Number of Cases of CDI — 103; 0 Participants

Primary: Percent of Patients With Return Toward a Normal Fecal Bile Acid Pattern — 100 percentage of participants

Primary: Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT) — 83.4; 82.1 Adjusted percentage of participants

Primary: Number of Participants With Clostridium Difficile Infection Recurrence. — 34; 21 Participants — p=0.56

Primary: Patient Demographics — 54; 46; 63; 29 participants

Primary: Pharmacokinetics of Tigecycline Along With Standard Treatments for Clostridium Difficile — 0.18 milligrams/liter

Primary: Number of First Primary Episodes of Clostridium Difficile Infection (CDI) (Definition 1) Follow-up After Dose 3 — 17; 25 Episodes

Primary: Cure Rate at End of Therapy — 85.7; 88.2 Percentage of Participants

Primary: Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment — 61; 58; 59 participants

Primary: To Assess if Probiotic Prophylaxis (BIO-K+CL1285®) is Effective for the Prevention of AAD in Hospitalized Patients. — 84; 85; 86 participants — p==0.02

Primary: Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT) — 79.0; 83.6 Percentage of participants

Primary: The Incidence of CDI in Inpatients Receiving Vancomycin Prophylaxis vs. Placebo Who Are on High-risk Antibiotics and Are Colonized With Toxigenic C. Difficile. — 0; 0…

Primary: Cure Rate at End of Therapy — 86.7; 87.7 Percentage of Participants

Primary: Number of Participants With Detectable C. Difficile — 5; 4 Participants

Primary: Presence of AAD — 12 participants — p=<0.05

Primary: Nitazoxanide — 27 participants

Primary: Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal…

Primary: Clinical Cure: Resolution of Diarrhea — 54; 44 Participants — p=0.195

Primary: Adjusted Geometric Mean Concentration (GMC) of Clostridium Difficile Toxin A and Toxin B Specific Neutralizing Antibodies at Month 7 for Evaluable Immunogenicity…

Primary: Incidence of Serious Adverse Events Through 56 Days After the Last Treatment With RBX2660 — 10 number of reported SAEs through 56 days

Primary: Percentage of Participants Reporting Prespecified Local Reactions Within 7 Days After Dose 1 (50- to 64-Year Age Cohort) — 16.7; 16.7; 50.0; 16.7 Percentage of…

Primary: Segment 2A: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI) Per Protocol (PP)/Modified Intent-to-Treat (mITT) Population — 10; 0 Participants

Primary: Number of Participants Reporting Solicited Injection Site Erythema and Tenderness Post-vaccination With Either One of Three Formulations of Clostridium Difficile…

Primary: Clostridium Difficile Infection Occurrence — 2; 0 Participants

Primary: C. Difficile Acquisition Rates — 13.2; 10.4 C. diff acquisition per patient days — p=0.611

Primary: Serum Anti-toxin A and Anti-toxin B Antibody Concentrations at Day 14 — 2083.3; 3189.4; 32096.4 EU/mL — p=0.5746